By Spyridon Bissas, NIHR Pre-doctoral Fellow at Imperial Clinical Trials Unit If a child does not receive (or does not use) a myopia-control intervention as intended, how confidently can we interpret its effect? Clinical trials evaluating interventions designed to slow myopia progression (commonly referred to as “myopia control”) typically involve modalities that require consistent and repeated use in everyday life, such as specialised spectacle and contact lenses, topical ap

By Annie Wright, NIHR BRC PhD Candidate based at Imperial Clinical Trials Unit (ICTU) Decentralisation is the concept of moving trial procedures, e.g. recruitment or consent, away from a central location and towards participants. Different ways of decentralising can occur across the lifecycle of a trial: Stage of the Trial Traditional Decentralised Recruitment Recruitment at the trial site, with participants speaking to study staff Online recruitment, remote screening Conse

By Manel Benlloch Guajardo and Martin Orr, Clinical Trials Statisticians at Imperial Clinical Trials Unit (ICTU) In June, members of the ICTU team attended the Critical Care Reviews meeting in Belfast. This stunning conference mixed groundbreaking critical care trials and independent editorials with the chance to experience first-hand the feeling of being in the Titanic grand staircase. A true blend of the novel and the antique. The conference delivered plenty of results but

By Victoria Cornelius, Professor in Medical Statistics and Clinical Trials The design stage of a clinical trial is my favourite part of being a medical statistician, as there is no single perfect design. Instead, it offers a chance to discover and explore differing options. One aspect that many trialists struggle with is how to size the trial. This is unsurprising, as while the basic sample size calculation is simple and quick to perform, there is a lot more to take into cons

By Dr David Hohenschurz-Schmidt, Postdoctoral Researcher in Pain Research and Trial Methods for Complex Interventions Blinding is a fundamental principle of high-quality randomised controlled trials. It involves withholding key information about treatment allocation from trial participants (and often investigators and outcome assessors). The aim is to balance expectations across study groups so that any observed treatment effects can be more confidently attributed to the inte